Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				GEM012 NCT00407303

First Published: 8/20/2007


2.		Phase I/II Study of Obatoclax Mesylate and Topotecan Hydrochloride in Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				MSKCC-07082 07-082, 7937, NCT00521144

Last Modified: 8/20/2008 First Published: 9/27/2007


3.		Phase I/II Study of Obatoclax Mesylate and Bortezomib in Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				Over 18				NCI				CCC-PHI-58 PHI-58, 7943, NCT00538187


4.		A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				GEM017 NCT00682981

Last Modified: 9/16/2008 First Published: 7/18/2008


5.		Phase I/II Study of Obatoclax Mesylate and Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				MAYO-MC068A MC068A, 7952, NCT00719901


6.		Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				70 and over				Pharmaceutical / Industry				GEM016 NCT00684918

Last Modified: 6/4/2008 First Published: 2/6/2008


7.		Phase I Study of Obatoclax Mesylate, Fludarabine Phosphate, and Rituximab in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				DFCI-07100 07-100, 7945, NCT00612612

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute